Skip to main content
Livermore
Livermore
ZHEN

NVP Associates, LLC

SEC CIK
0001545692
Latest filing
Aug 7, 2026

The latest 13F from NVP Associates, LLC covers Q2 2026 (filed Aug 7, 2026): 7 long positions worth $328.2M. The top 10 holdings make up 100.0% of the portfolio, and the largest is MBX Biosciences, Inc. (MBX) at 35.9%. Livermore has 15 filings on Form 13F from this institution, going back to Q4 2022.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
3
Est. +$104.0M
Added
0
Reduced
0
Sold out
1
Est. −$40.5M

Top 5 holdings

Share of this quarter's portfolio value

  1. MBXMBX Biosciences, Inc.
    35.9%$117.9MHistory
  2. AVLNAvalyn Pharma Inc.
    22.8%$74.7MHistory
  3. OMDAOmada Health, Inc.
    16.9%$55.6MHistory
  4. ZBIOZenas BioPharma, Inc.
    14.2%$46.7MHistory
  5. SNOWSnowflake Inc.
    8.9%$29.2MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. AVLNAvalyn Pharma Inc.
    +$74.7MNewHistory
  2. SNOWSnowflake Inc.
    +$29.2MNewHistory
  3. ONDSOndas Inc.
    +$128.6KNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AVLNAvalyn Pharma Inc.
    +22.75 pp0.0% → 22.8%History
  2. SNOWSnowflake Inc.
    +8.90 pp0.0% → 8.9%History
  3. ONDSOndas Inc.
    +0.04 pp0.0% → <0.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. BLLNBillionToOne, Inc.
    −$40.5MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. BLLNBillionToOne, Inc.
    −23.00 pp23.0% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$328.2M
+$152.0M (+86.3%) vs. prior quarter
Positions
7
+2 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
16.1%
Q2 2026, one quarter
Average holding period
5.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2022), so positions held before then are understated.

13F filings by quarter

15 quarters, going back to Q4 2022. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $328.2M (Q2 2026)

Q4 2022: $102.5MQ1 2023: $86.9MQ2 2023: $114.6MQ3 2023: $111.7MQ4 2023: $112.1MQ1 2024: $125.9MQ2 2024: $91.3MQ3 2024: $176.1MQ4 2024: $186.9MQ1 2025: $112.2MQ2 2025: $184.2MQ3 2025: $166.1MQ4 2025: $255.2MQ1 2026: $176.2MQ2 2026: $328.2M
Q4 2022Q2 2026
13F filings of NVP Associates, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 7, 20267$328.2MMBXAVLNOMDAvs. Q1 2026SEC
Q1 2026May 15, 20265$176.2MMBXBLLNZBIOvs. Q4 2025SEC
Q4 2025Feb 17, 20266$255.2MMBXZBIOBLLNvs. Q3 2025SEC
Q3 2025Nov 14, 20255$166.1MOMDAZBIOMBXvs. Q2 2025SEC
Q2 2025Aug 14, 20257$184.2MDAVEOMDATALKvs. Q1 2025SEC
Q1 2025May 12, 20256$112.2MDAVETALKMBXvs. Q4 2024SEC
Q4 2024Feb 10, 20257$186.9MDAVETALKMBXvs. Q3 2024SEC
Q3 2024Nov 12, 20248$176.1MMBXZBIOTALKvs. Q2 2024SEC
Q2 2024Aug 13, 20246$91.3MTALKUDMYDAVEvs. Q1 2024SEC
Q1 2024May 10, 20246$125.9MTALKUDMYDAVEvs. Q4 2023SEC
Q4 2023Feb 14, 20246$112.1MUDMYTALKOPENvs. Q3 2023SEC
Q3 2023Nov 8, 20238$111.7MUDMYTALKOPENvs. Q2 2023SEC
Q2 2023Aug 1, 20239$114.6MUDMYTALKOPENvs. Q1 2023SEC
Q1 2023May 15, 20238$86.9MUDMYTALKOPENvs. Q4 2022SEC
Q4 2022Feb 14, 20238$102.5MUDMYIMPLTALK–SEC

13D and 13G filings

Companies where NVP Associates, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

NVP Associates, LLC does not currently report owning 5% or more of any company.

Latest filings

3 filings on file made by NVP Associates, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by NVP Associates, LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
MBXMBX Biosciences, Inc.Sep 30, 20256:15 PM ETNorwest Venture Partners XVI, LPand 5 others13D/A4.80%2.14M shares–Below 5%Sep 26, 2025SEC
DAVEDave Inc.Aug 14, 20254:57 PM ETNorwest Venture Partners XIV, LPand 4 others13G/A2.00%232.7K shares–Below 5%Jun 30, 2025SEC
TALKTalkspace, Inc.May 15, 20255:31 PM ETNorwest Venture Partners XIII, LPand 5 others13G/A5.90%9.85M shares–Mar 31, 2025SEC